WO2004005930A3 - Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases - Google Patents

Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases Download PDF

Info

Publication number
WO2004005930A3
WO2004005930A3 PCT/DE2003/002288 DE0302288W WO2004005930A3 WO 2004005930 A3 WO2004005930 A3 WO 2004005930A3 DE 0302288 W DE0302288 W DE 0302288W WO 2004005930 A3 WO2004005930 A3 WO 2004005930A3
Authority
WO
WIPO (PCT)
Prior art keywords
neurodegenerative diseases
diagnosis
human
pharmaceutical substances
diseases
Prior art date
Application number
PCT/DE2003/002288
Other languages
German (de)
French (fr)
Other versions
WO2004005930A2 (en
Inventor
Michael Wilhelm
Vladimir Agueev
Original Assignee
Merdiquant Gmbh
Michael Wilhelm
Vladimir Agueev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merdiquant Gmbh, Michael Wilhelm, Vladimir Agueev filed Critical Merdiquant Gmbh
Priority to AU2003247252A priority Critical patent/AU2003247252A1/en
Publication of WO2004005930A2 publication Critical patent/WO2004005930A2/en
Publication of WO2004005930A3 publication Critical patent/WO2004005930A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Abstract

The invention relates to the use of known pharmaceutical substances chloropromazine, ethacrine, quinacrine, lovastatine, doxorubicine and D-penicillamine for the diagnosis of human and animal neurodegenerative diseases such prion diseases as TSE diseases suc has BSE, CJD, vCJD, scrapie and other neurodegenerative diseases based on the formation of neurotoxic amyloid plaques. Body fluids such as whole blood, plasma, serum, liquor, urine, milk, lymph, lymph plasma and saliva, i.e. body fluids containing proteins, are used as test media. Previously, said substances were used therapeutically as psychopharmaceuticals, cycostatics, lipid reducres, antirheumatics and antiparasite agents. The invention also relates to a method for the diagnosis of human and animal neurodegenerative diseases, wherein said pharmaceutical substances are used.
PCT/DE2003/002288 2002-07-04 2003-07-03 Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases WO2004005930A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2003247252A AU2003247252A1 (en) 2002-07-04 2003-07-03 Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10230838.1 2002-07-04
DE2002130838 DE10230838B4 (en) 2002-07-04 2002-07-04 Diagnostic use of pharmaceutical substances

Publications (2)

Publication Number Publication Date
WO2004005930A2 WO2004005930A2 (en) 2004-01-15
WO2004005930A3 true WO2004005930A3 (en) 2004-03-18

Family

ID=29761777

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DE2003/002288 WO2004005930A2 (en) 2002-07-04 2003-07-03 Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases

Country Status (3)

Country Link
AU (1) AU2003247252A1 (en)
DE (1) DE10230838B4 (en)
WO (1) WO2004005930A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103172604B (en) * 2011-12-22 2015-06-24 北大方正集团有限公司 Lovastatin purification method combining auxiliary magnetic crystallization

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981208A (en) * 1992-04-09 1999-11-09 Bayer Corporation Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein
DE10130727A1 (en) * 2001-06-21 2003-01-09 Mediquant Gmbh Method and device for measuring micro-viscosity changes as an immunoassay

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908059D0 (en) * 1999-04-09 1999-06-02 Imp College Innovations Ltd Diagnosis and treatment of diseases
US6589504B1 (en) * 2000-09-22 2003-07-08 Pharmacia & Upjohn Company Compounds and methods for diagnosing and treating amyloid-related conditions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981208A (en) * 1992-04-09 1999-11-09 Bayer Corporation Diagnostic assay for Alzheimer's disease based on the proteolysis of the amyloid precursor protein
DE10130727A1 (en) * 2001-06-21 2003-01-09 Mediquant Gmbh Method and device for measuring micro-viscosity changes as an immunoassay

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BORANIC M ET AL: "A PARKINSON-LIKE SYNDROME AS SIDE EFFECT OF CHEMO THERAPY WITH VINCRISTINE AND ADRIAMYCIN IN A CHILD WITH ACUTE LEUKEMIA", BIOMEDICINE EXPRESS (PARIS), vol. 31, no. 5, 1979, pages 124 - 125, XP009019730, ISSN: 0300-0885 *
PAHAN K ET AL: "LOVASTATIN AND PHENYLACETATE INHIBIT THE INDUCTION OF NITRIC OXIDE SYNTHASE AND CYTOKINES IN RAT PRIMARY ASTROCYTES, MICROGLIA, AND MACROPHAGES", JOURNAL OF CLINICAL INVESTIGATION, NEW YORK, NY, US, vol. 100, no. 11, December 1997 (1997-12-01), pages 2671 - 2679, XP002917163, ISSN: 0021-9738 *
PETERS L ET AL: "D-Penicillamine metabolism in neurodegenerative diseases: An in vivo/in vitro sulphydryl methylation study", XENOBIOTICA 1994 UNITED KINGDOM, vol. 24, no. 10, 1994, pages 1013 - 1020, XP009019643, ISSN: 0049-8254 *

Also Published As

Publication number Publication date
DE10230838A9 (en) 2004-09-09
DE10230838B4 (en) 2005-02-03
WO2004005930A2 (en) 2004-01-15
AU2003247252A1 (en) 2004-01-23
DE10230838A1 (en) 2004-01-22

Similar Documents

Publication Publication Date Title
Bittar et al. Advances and considerations in AD tau-targeted immunotherapy
Walsh et al. The oligomerization of amyloid β-protein begins intracellularly in cells derived from human brain
Park et al. Lovastatin enhances Aβ production and senile plaque deposition in female Tg2576 mice
Qing et al. Degradation of BACE by the ubiquitin‐proteasome pathway
Sennvik et al. Levels of α-and β-secretase cleaved amyloid precursor protein in the cerebrospinal fluid of Alzheimer's disease patients
Chyung et al. Inhibition of receptor-mediated endocytosis demonstrates generation of amyloid β-protein at the cell surface
Maruyama et al. Cerebrospinal fluid neprilysin is reduced in prodromal Alzheimer's disease
Chintamaneni et al. Biomarkers in Alzheimer's disease: a review
Ray et al. Biochemical studies in normal pressure hydrocephalus (NPH) patients: change in CSF levels of amyloid precursor protein (APP), amyloid-beta (Aβ) peptide and phospho-tau
Lai et al. Inhibition of amyloid-beta peptide aggregation rescues the autophagic deficits in the TgCRND8 mouse model of Alzheimer disease
Ghanevati et al. Phospho-β-catenin accumulation in Alzheimer’s disease and in aggresomes attributable to proteasome dysfunction
Mamada et al. Amyloid β-protein oligomers upregulate the β-secretase, BACE1, through a post-translational mechanism involving its altered subcellular distribution in neurons
van Weering et al. Endolysosome and autolysosome dysfunction in Alzheimer’s disease: where intracellular and extracellular meet
de Almeida et al. Opposing effects of cucurbit [7] uril and 1, 2, 3, 4, 6-penta-O-galloyl-β-d-glucopyranose on amyloid β25–35 assembly
Lin et al. Region-specific expression of tau, amyloid-β protein precursor, and synaptic proteins at physiological condition or under endoplasmic reticulum stress in rats
Nagamine et al. Hypersialylation is a common feature of neurofibrillary tangles and granulovacuolar degenerations in Alzheimer's disease and tauopathy brains
WO2009100953A3 (en) Diagnostic method
Lagalwar et al. Relation of hippocampal phospho-SAPK/JNK granules in Alzheimer’s disease and tauopathies to granulovacuolar degeneration bodies
US20200132683A1 (en) Rapid multiplex diagnostic for parkinson's disease and alzheimer's disease
Nutu et al. Aβ1-15/16 as a potential diagnostic marker in neurodegenerative diseases
WO2004005930A3 (en) Diagnostic use of pharmaceutical substances and method for the diagnosis of human and animal neurodegenerative diseases
Zetterberg et al. Cerebrospinal fluid analysis should be considered in patients with cognitive problems
JP5677297B2 (en) Glutaminyl cyclase as an indicator for diagnosis / prognosis of neurodegenerative diseases
Winkler et al. Rapid cerebral amyloid binding by Aβ antibodies infused into β-amyloid precursor protein transgenic mice
R Sadleir et al. Elevated Aβ42 in aged, non-demented individuals with cerebral atherosclerosis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AU BA BG BR CA CN CO CR CU CZ DM DZ EC EE HR HU ID IL IN IS JP KP KR LK LR LT LV MA MD MK MN MX NO NZ PL RO SG SK TR TT UA US UZ VN YU ZA

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP

122 Ep: pct application non-entry in european phase